Drugs / T-Dxd
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06253871 Background | Mar 2024 → Dec 2027 expected | HER2 positive breast carcinoma, gastroesophageal cancer, metastatic malignant neoplasm in the brain, non-small cell lung carcinoma +1 | Iambic Therapeutics, Inc | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-Dxd | “IAM1363 monotherapy OR IAM1363 in combination with capecitabine + trastuzumab OR IAM1363 in combination with capecitabine + zanidatamab OR IAM1363 in combination with T-Dxd OR...” NCT06253871 ↗ |